Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.

ABSTRACT:

Background

Sickle Cell Disease (SCD) is a progressive genetic disease that causes organ damage and reduces longevity. Hydroxyurea is an underutilized evidence-based medication that reduces complications and improves survival in SCD. In a multi-site clinical trial, part of the NIH-funded Sickle Cell Disease Implementation Consortium (SCDIC), we evaluate the implementation of a multi-level and multi-component mobile health (mHealth) patient and provider intervention to target the determinants and context of low hydroxyurea use. Given the complexity of the intervention and contextual variability in its implementation, we combined different behavioral and implementation theories, models, and frameworks to facilitate the evaluation of the intervention implementation. In this report, we

SUBMITTER: Hankins JS 

PROVIDER: S-EPMC10012741 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature